Radioactive Iodine — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	0	0	2	2	0	—	—	2000-01

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 17 hours agoSource updated unknown

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
GNAS R201H1
Radioactive Iodine	Thyroid Gland Follicular Carcinoma

Clinical trials

Trials with this intervention (2)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05142904	Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules(RABITO)	terminated	Phase 3	40	Rijnstate HospitalOTHER	1	Jul 17, 2025	clinicaltrials
NCT00115895	The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy	unknown